In this nationwide population-based study using real-world data, the OS of patients with stage IV NSCLC with a KRAS G12C versus a non-G12C mutation was similar, when treated with first-line monoimmunotherapy or combination chemoimmunotherapy. Here, KRAS is linked to non-small cell lung carcinoma.